Coagulation factor VIII haemophilia

Some 5-25 per cent of individuals suffering from haemophilia A develop anti-factor VIII antibodies, and 3-6 per cent of haemophilia B sufferers develop anti-factor IX antibodies. This complicates treatment of these conditions and, as mentioned previously, one approach to their treatment is direct administration of factor Vila. The therapeutic rationale is that factor Vila could directly activate the final common steps of the coagulation cascade, independently of either factor VIII or IX (Figure 12.1). Factor Vila forms a complex with tissue factor that, in the presence of phospholipids and Ca2+, activates factor X. 

Lechner D, Eichinger S, Wanivenhaus A, Kyrle PA. Peri-interventional control of haemostasis in a patient with combined coagulation factor V- and factor VIII-deflciency and anaphylaxis to fresh frozen plasma—a rare indication for recombinant factor Vila. Haemophilia 2010 16(4) 704-5. 

Cryoprecipitate is a blood product that is manufactured from fresh frozen plasma. It contains a subset of coagulation factors fibrinogen (minimum of 150mg/unit), factor VIII (minimum 80IU/unit), von Willebrand factor (VWF) and factor XIII. With the production of recombinant and purified factor concentrates, the classical indications of haemophilia A and von Willebrand disease are no longer appropriate. Currently, cryoprecipitate is used to treat hypofibrinogemia. 

Blood coagulation factors e.g. factor VIII 330 kDa Human blood Used to treat haemophilia... 

---